Assignee
ARSTAT INC
US·12 granted patents·7 pending applications·5 citations·filing 2013–2022
Top patents by PatentIndex Score
19 records- 0187US11116718B2Treatment of endometriosis by intravaginal administration of a low dose of a selective progesterone receptor modulator (SPRM), anti-progestin, or anti-progestational agentARSTAT INC·Filed 2019·Granted Sep 14, 2021·2 cites·6 claims
- 0285US10251836B2Treatment of endometriosis by intravaginal administration of a low dose of a selective progesterone receptor modulator (SPRM), anti-progestin, or anti-progestational agentARSTAT INC·Filed 2013·Granted Apr 9, 2019·3 cites·8 claims
- 0380US11833126B2Oral combination drug formulation comprising a non-steroidal anti-inflammatory drug and a complementary low dose of tranexamic acid for the treatment of menstrual pain accompanied with excessive menstrual blood lossARSTAT INC·Filed 2022·Granted Dec 5, 2023·0 cites·13 claims
- 0478US11103515B2Multiphasic contraceptive regimen for oral combination drug formulation of progestin and estrogenARSTAT INC·Filed 2019·Granted Aug 31, 2021·0 cites·12 claims
- 0577US10709679B2Oral combination drug formulation comprising a non-steroidal anti-inflammatory drug and a complementary low dose of tranexamic acid for the treatment of menstrual pain accompanied with excessive menstrual blood lossARSTAT INC·Filed 2019·Granted Jul 14, 2020·0 cites·13 claims
- 0672US11351132B2Oral combination drug formulation comprising a non-steroidal anti-inflammatory drug and a complementary low dose of tranexamic acid for the treatment of menstrual pain accompanied with excessive menstrual blood lossARSTAT INC·Filed 2020·Granted Jun 7, 2022·0 cites·13 claims
- 0770US10537582B2Multiphasic contraceptive regimen for oral combination drug formulation of progestin and estrogenARSTAT INC·Filed 2019·Granted Jan 21, 2020·0 cites·12 claims
- 0868US10463678B2Multiphasic contraceptive regimen for oral combination drug formulation of progestin and estrogenARSTAT INC·Filed 2018·Granted Nov 5, 2019·0 cites·6 claims
- 0967US10532037B2Oral combination drug formulation comprising a non-steroidal anti-inflammatory drug and a complementary low dose of tranexamic acid for the treatment of menstrual pain accompanied with excessive menstrual blood lossARSTAT INC·Filed 2019·Granted Jan 14, 2020·0 cites·13 claims
- 1067US10111887B2Multiphasic contraceptive regimen for oral combination drug formulation of progestin and estrogenARSTAT INC·Filed 2018·Granted Oct 30, 2018·0 cites·12 claims
- 1165US9675622B2Multiphasic contraceptive regimen for oral combination drug formulation of progestin and estrogenARSTAT INC·Filed 2014·Granted Jun 13, 2017·0 cites·12 claims
- 1264US9925199B2Multiphasic contraceptive regimen for oral combination drug formulation of progestin and estrogenARSTAT INC·Filed 2017·Granted Mar 27, 2018·0 cites·12 claims
- 1361US2019201418A1Treatment of uterine fibroids by intravaginal administration of a low dose of selective progesterone receptor modulator (sprm), anti-progestin, or anti-progestational agentARSTAT INC·Filed 2019·Application pending·0 cites
- 1460US2014039054A1Oral combination drug formulation comprising a non-steroidal anti-inflammatory drug and a complementary low dose of tranexamic acid for the treatment of menstrual pain accompanied with excessive menstrual blood lossARSTAT INC·Filed 2013·Application pending·0 cites
- 1559US2014005157A1Treatment of uterine fibroids by intravaginal administration of a low dose of selective progesterone receptor modulator (sprm), anti-progestin, or anti-progestationalARSTAT INC·Filed 2013·Application pending·0 cites
- 1659US2013345678A1Treatment of excessive menstrual blood loss by feminine sanitary products medicated with antifibrinolytic or hemostatic agentARSTAT INC·Filed 2013·Application pending·0 cites
- 1753US2019151634A1Treatment of excessive menstrual blood loss by feminine sanitary products medicated with hemostatic agentARSTAT INC·Filed 2019·Application pending·0 cites
- 1850US2014030313A1Treatment of menstrual pain and excessive menstrual blood loss by intravaginal administration of a low dose of antifibrinolytic or hemostatic agent in combination with non-steroidal anti-inflammatory drugARSTAT INC·Filed 2013·Application pending·0 cites
- 1950US2013337054A1Treatment of excessive menstrual blood loss by intravaginal administration of low doses of antifibrinolytic or hemostatic agentARSTAT INC·Filed 2013·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when ARSTAT INC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →